Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ABSTRACT: Mycobiome in Pancreatic Cancer

PROVIDER: PRJNA557226 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR14193735.fastq.gz	Fastqsanger.gz
	SRR14193736.fastq.gz	Fastqsanger.gz
	SRR9856280.fastq.gz	Fastqsanger.gz
	SRR9856290.fastq.gz	Fastqsanger.gz
	SRR9856300.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 164

Similar Datasets

Fungal mycobiome drives IL33 secretion and type 2 immunity in pancreatic cancer

Project description:We report the RNAseq of mouse pancreatic cancer cell lines with Kras ON vs Kras OFF. TH2 and innate lymphoid cells 2 (ILC2) can stimulate tumor growth by secreting pro-tumorigenic cytokines such as IL4, IL5 and IL13. However, the mechanisms by which type 2 immune cells traffic to the tumor microenvironment (TME) are unknown. Here, in pancreatic ductal adenocarcinoma (PDAC), we show that oncogenic KrasG12D (Kras*) increases the expression of IL33 in cancer cells, which upon secretion recruits and activates the TH2 and ILC2. Correspondingly, cancer cell-specific deletion of IL33 reduces TH2 and ILC2 recruitment and promotes tumor regression. Unexpectedly, we discovered that the cellular release of IL33 into the TME is dependent on the intratumoral fungal mycobiome. Genetic deletion of IL33 or anti-fungal treatment decreases TH2 and ILC2 infiltration and increases survival. Consistent with these murine data, high IL33 expression is observed in approximately 20% of human PDAC, and expression is mainly restricted to cancer cells. These data expand our knowledge of the mechanisms driving PDAC tumor progression and identifies therapeutically targetable pathways involving intratumoral mycobiome-driven secretion of IL33.

2022-03-01 | GSE190468 | GEO

Fungal mycobiome drives IL33 secretion and type 2 immunity in pancreatic cancer

Project description:TH2 and innate lymphoid cells 2 (ILC2) can stimulate tumor growth by secreting pro-tumorigenic cytokines such as IL4, IL5 and IL13. However, the mechanisms by which type 2 immune cells traffic to the tumor microenvironment (TME) are unknown. Here, in pancreatic ductal adenocarcinoma (PDAC), we show that oncogenic KrasG12D (Kras*) increases the expression of IL33 in cancer cells, which upon secretion recruits and activates the TH2 and ILC2. Correspondingly, cancer cell-specific deletion of IL33 reduces TH2 and ILC2 recruitment and promotes tumor regression. Unexpectedly, we discovered that the cellular release of IL33 into the TME is dependent on the intratumoral fungal mycobiome. Genetic deletion of IL33 or anti-fungal treatment decreases TH2 and ILC2 infiltration and increases survival. Consistent with these murine data, high IL33 expression is observed in approximately 20% of human PDAC, and expression is mainly restricted to cancer cells. These data expand our knowledge of the mechanisms driving PDAC tumor progression and identifies therapeutically targetable pathways involving intratumoral mycobiome-driven secretion of IL33.

2022-03-01 | GSE190103 | GEO

THE ORAL MYCOBIOME AND RISK OF PANCREATIC CANCER

Project description:THE ORAL MYCOBIOME AND RISK OF PANCREATIC CANCER

| PRJNA1242418 | ENA

THE ORAL MYCOBIOME AND RISK OF PANCREATIC CANCER

Project description:THE ORAL MYCOBIOME AND RISK OF PANCREATIC CANCER

| PRJNA1242417 | ENA

Fungal mycobiome drives IL33 secretion and type 2 immunity in pancreatic cancer

Project description:Fungal mycobiome drives IL33 secretion and type 2 immunity in pancreatic cancer

| PRJNA785869 | ENA

KRAS On vs OFF mouse cell lines

Project description:Fungal mycobiome drives IL33 secretion and type 2 immunity in pancreatic cancer

| PRJEB49092 | ENA

Fungal mycobiome drives IL33 secretion and type 2 immunity in pancreatic cancer

Project description:Fungal mycobiome drives IL33 secretion and type 2 immunity in pancreatic cancer

| PRJNA787243 | ENA

GNPS - Metabolomic analysis of exosome of pancreatic cancer

Project description:Metabolomics analysis of serum exosomes isolated from pancreatic cancer patients and healthy controls.

2019-04-06 | MSV000083669 | GNPS

Exploring the female genital tract mycobiome in young South African women using metaproteomics

Project description:Female genital tract (FGT) diseases such as bacterial vaginosis (BV) and sexually transmitted infections are prevalent in South Africa, with young women being at an increased risk. Since imbalances in the FGT microbiome are associated with FGT diseases, it is vital to investigate the factors that influence FGT health. The mycobiome plays an important role in regulating mucosal health, especially when the bacterial component is disturbed. However, we have a limited understanding of the FGT mycobiome since many studies have focused on bacterial communities and have neglected low abundance taxonomic groups, such as fungi. To reduce this knowledge deficit, we present the first large-scale metaproteomic study to define the taxonomic composition and potential functional processes of the FGT mycobiome in South African reproductive-age women. We examined FGT fungal communities present in 123 women by collecting lateral vaginal wall swabs for liquid chromatography-tandem mass spectrometry.

2025-03-28 | PXD046053 | Pride

human metagenome

Project description:Mycobiome characterization in Lung Cancer

| PRJNA586768 | ENA